Intracellular plutonium: removal by liposome-encapsulated chelating agent

Area of Science:

• Biochemistry
• Pharmacology
• Nanotechnology

Background:

• Metal poisoning poses significant health risks.
• Conventional chelating agents have limitations in cellular targeting and efficacy.
• Ethylenediaminetetraacetic acid (EDTA) and diethylenetriaminepentaacetic acid (DTPA) are key chelating agents.

Purpose of the Study:

• To investigate the efficacy of liposome-encapsulated chelating agents for metal poisoning treatment.
• To evaluate the pharmacokinetic and therapeutic advantages of encapsulated EDTA and DTPA.

Main Methods:

• Liposomes were synthesized to encapsulate EDTA and DTPA.
• Encapsulated and non-encapsulated [(14)C]EDTA were administered intravenously to mice for retention studies.
• Encapsulated DTPA was administered to mice post-plutonium injection to assess plutonium removal and excretion.

Main Results:

• Liposomal encapsulation successfully entrapped EDTA and DTPA.
• Encapsulated [(14)C]EDTA exhibited prolonged retention in mouse tissues compared to non-encapsulated form.
• Encapsulated DTPA significantly enhanced plutonium removal from the liver and increased urinary excretion in mice.

Conclusions:

• Liposomal encapsulation enhances the therapeutic potential of chelating agents like EDTA and DTPA.
• This approach facilitates intracellular delivery of chelators, improving treatment for metal poisoning.
• Liposomal chelation therapy represents a promising strategy for managing heavy metal toxicity.